GordonMD Global Investments
VC Fund
Beverly Hills, United States
GordonMD Global Investments is a VC fund in Beverly Hills focused on Biotechnology and Therapeutics. GordonMD Global Investments focused on investments in private and publicly traded global growth and innovative biopharma companies.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries GordonMD Global Investments invests in
Stages GordonMD Global Investments invests in
Countries GordonMD Global Investments invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Craig Gordon
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 13 (87%)
- Therapeutics 9 (60%)
- Health Care 6 (40%)
- Life Science 5 (33%)
- Genetics 4 (27%)
Stage
- Series B 5 (33%)
- Series A 3 (20%)
- Series C 3 (20%)
- Post-IPO Equity 3 (20%)
- Seed 1 (7%)
Country
- United States 13 (87%)
- France 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Craig Gordon
Founder, CEO, and CIO
|
Founder, CEO, and CIO | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cyllene Therapeutics
|
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. | $37.7M / Series C / Jul 07, 2026 | |
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Pyxis Oncology
|
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $50M / Post-IPO Equity / Jun 30, 2026 | |
Rapalogix Health
|
Rapalogix Health is a biotechnology company. | $20M / Series A / Jun 23, 2026 | |
Stipple Bio
|
Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied inoncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity. | $100M / Series A / Apr 06, 2026 | |
Soley Therapeutics
|
Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs, using image acquisition-based approaches.Soley Therapeutics has taken an orthogonal approach to discover new drugs by developing a technology platform to measure how cells respond multi-dimensionally in response to drugs. We havedeveloped a novel platform for high-content phenotypic drug screening, where the drug effect on a cell can be visualized via molecular-microscopic images and analyzed by using sophisticated AI tools. | $200M / Series C / Jan 07, 2026 | |
|
Amlogenyx
|
Amlogenyx is a novel gene therapeutics company that focuses on developing lysosome-based treatments for Alzheimer's disease. It is a spin-off from Ultragenyx Pharmaceutical. | $14M / Seed / Aug 02, 2024 | |
Crinetics Pharmaceuticals
|
Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost toachieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products. | $350M / Post-IPO Equity / Feb 28, 2024 | |
Taysha Gene Therapies
|
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $150M / Post-IPO Equity / Aug 14, 2023 | |
Radionetics Oncology
|
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics. | $52.5M / Series A / Aug 14, 2023 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does GordonMD Global Investments invest in?
GordonMD Global Investments invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GordonMD Global Investments?
Public channels for GordonMD Global Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GordonMD Global Investments?
The team at GordonMD Global Investments includes Craig Gordon (Founder, CEO, and CIO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
